Apogee Therapeutics (APGE) Total Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Liabilities data on file, last reported at $37.9 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 7.2% year-over-year to $37.9 million in Q1 2026; TTM through Mar 2026 was $37.9 million, a 7.2% decrease from a year earlier, with the FY2025 full-year figure at $33.3 million, down 10.51% from the prior year.
• Total Liabilities for Q1 2026 stood at $37.9 million, up from $33.3 million in the prior quarter.
• Over the last five years, Total Liabilities for APGE reached as high as $41.9 million in Q3 2024 and fell as low as $10.0 million in Q4 2022.
• Historically, Total Liabilities has averaged $29.6 million across 5 years, with a median of $33.3 million in 2025.
• Across the five-year window, Total Liabilities jumped 143.82% in 2024 and decreased 10.51% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $10.0 million in 2022, then soared by 115.34% to $21.5 million in 2023, then soared by 72.9% to $37.2 million in 2024, then fell by 10.51% to $33.3 million in 2025, then increased by 13.86% to $37.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $37.9 million in Q1 2026, $33.3 million in Q4 2025, and $39.8 million in Q3 2025.